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complex induces apolipoprotein overexpression and
systemic amyloidosis in mice
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Andrea Bozovic,5,6 Vathany Kulasingam,5,6 and Frederick A. Dick1,3,4,7
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DREAM (Dp, Rb-like, E2F, and MuvB) is a transcriptional repressor complex that regulates cell proliferation, and its loss
causes neonatal lethality in mice. To investigate DREAM function in adult mice, we used an assembly-defective p107 protein
and conditional deletion of its redundant family member p130. In the absence of DREAM assembly, mice displayed shortened
survival characterized by systemic amyloidosis but no evidence of excessive cellular proliferation. Amyloid deposits were
found in the heart, liver, spleen, and kidneys but not the brain or bone marrow. Using laser-capture microdissection followed
by mass spectrometry, we identified apolipoproteins as the most abundant components of amyloids. Intriguingly, apoA-IV
was the most detected amyloidogenic protein in amyloid deposits, suggesting apoA-IV amyloidosis (AApoAIV). AApoAIV
is a recently described form, whereby WT apoA-IV has been shown to predominate in amyloid plaques. We determined by
ChIP that DREAM directly regulated Apoa4 and that the histone variant H2AZ was reduced from the Apoa4 gene body in
DREAM’s absence, leading to overexpression. Collectively, we describe a mechanism by which epigenetic misregulation causes
apolipoprotein overexpression and amyloidosis, potentially explaining the origins of nongenetic amyloid subtypes.

Introduction

Amyloidosis is a disease characterized by the misfolding and
aggregation of proteins into ordered β-sheet fibrils that are deposited extracellularly within organs or tissues (1). Presently, there
are over 35 proteins known to be amyloidogenic in humans, which
has led to the classification of amyloidosis into different subtypes
based on the causative protein and the organs or tissues affected
(2, 3). Systemic amyloidosis involves multiple organs and/or tissues as a result of protein deposition at distal sites due to circulation (4). Several members of the apolipoprotein family have been
associated with systemic amyloidosis, including apolipoprotein
A-I (apoA-I), apolipoprotein A-II (apoA-II), and apolipoprotein
A-IV (apoA-IV, ref. 5). These proteins are predominantly made in
the liver, although their expression has also been reported in the
heart and spleen (6–8). ApoA-I and apoA-II are constituents of
HDL and are commonly implicated in hereditary amyloidosis (9,
10). ApoA-IV can exist as part of HDL or circulate in a lipid-free
state (11–13). Like apolipoprotein E (apoE) and serum amyloid
P-component (APCS), apoA-IV was originally considered to be
an amyloid signature protein present in many different amyloid
pathologies (14, 15). However, new mass spectrometry–based
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methods of characterizing protein identities have indicated that
apoA-IV has amyloidogenic properties, leading to the clinical designation of apoA-IV amyloidosis (AApoAIV) (16). Importantly, the
expansion of protein identities in amyloidosis revealed by mass
spectrometry creates a more complex landscape of disease etiology and raises new questions on the origins of nonhereditary forms
of the disease.
Epigenetic mechanisms often govern gene expression levels in
eukaryotic cells. In particular, deposition of nucleosomes containing the histone variant H2AZ represses gene expression in a number of biological scenarios through its accumulation in target genes
(17–19). A key regulator of H2AZ is the DREAM (Dp, Rb-like, E2F,
and MuvB) complex that possesses nucleosome binding activity
and is thought to function as a chaperone to deposit H2AZ at its
target genes (17, 20). DREAM was initially described as a cell cycle
regulatory complex that targets proliferation-related genes through
a bipartite promoter element composed of a cell cycle homology
region (CHR) and a cell cycle–dependent element (CDE) (17, 20,
21). These elements are well conserved in metazoan promoters,
and much of our understanding of DREAM regulation is derived
from cell proliferation studies in culture (22, 23) or development
in fruit flies and worms (24–26). In fruit flies, DREAM not only
represses transcription, but also associates with MYB-like proteins
to serve as a transcriptional activator (27). In mammals, DREAM
disassembles upon the initiation of proliferation and is replaced at
promoters by MYB-containing complexes that activate transcription (23). For this reason, it is unclear whether DREAM deficiency
1
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in lower organisms can be related to its physiological role in mammals, particularly because many phenotypes relate to fruit fly– and
worm-specific aspects of gonadal development (21, 26).
In mammals, under quiescent conditions DREAM is comprised of a DP protein, an RB family protein (either p107 or p130),
an E2F, and the MuvB core of proteins (made up of LIN9, LIN37,
LIN52, LIN54, and RBBP4, refs. 21, 28). Upon cell cycle entry,
DREAM is disassembled and the MuvB core partners with B-MYB
to form MYB-MuvB complexes that activate gene expression
required for progression through mitosis (28–30). Consequently,
mammalian DREAM function has been difficult to study because
all of its components have non-DREAM functions, and deletions
of their encoding genes in mice have resulted in embryonic or neonatal lethality (31–34). Consequently, much of our knowledge of
DREAM function in mammals is largely derived from cell culture
experiments investigating proliferative control, leaving its role in
mammalian physiology largely unexplored.
To circumvent the early developmental consequences of
DREAM loss, we devised a conditional model for inactivation of
DREAM in adult mice. We utilized tamoxifen-inducible deletion
of the p130-encoding gene (35) in combination with a constitutive
p107 mutant that is unable to interact with the MuvB core (36).
Therefore, these mice expressed the components of DREAM, but
were unable to assemble the complex. We showed that these mice
had diminished survival, exhibited symptoms of renal failure, and
developed systemic amyloidosis affecting the heart, kidney, liver,
and spleen. Transcriptional and proteomic analyses demonstrated that Apoa4 was overexpressed in the liver and apoA-IV was the
most abundant protein found in amyloids of these mice. ChIP analyses demonstrated that DREAM was replaced by B-MYB at the promoter of Apoa4 with a concurrent decreased localization of H2AZ
within the gene body. These data reveal a connection between
DREAM, altered epigenetic regulation of hepatic apolipoprotein
expression, and development of systemic AApoA-IV amyloidosis.

Results

Generation of adult DREAM assembly–deficient mice. The early
lethality of mice deficient for DREAM components limits insight
into DREAM assembly function in mammals. Consequently, we
generated a conditional mouse model to disrupt DREAM complex
assembly in young adult animals by eliminating the physical contact between the MuvB subunit LIN52 and p107/p130 (Figure 1A).
We utilized a previously described missense allele of Rbl1 in which
the encoded p107 protein is unable to interact with LIN52 (refs.
36, 37 and Figure 1A). Since this mutation leaves p130 available
to participate in DREAM assembly, we employed a ubiquitously
expressed UBC-Cre-ERT2 system to conditionally delete Rbl2
(that encodes p130) in adult mice and prevent DREAM assembly (ref. 38 and Figure 1A). The inability to assemble DREAM has
previously been shown to result in ectopic MYB-MuvB assembly
at DREAM-regulated genes, even in growth-arrested conditions
(refs. 23, 36 and Figure 1A); therefore, we first sought to determine
whether tamoxifen treatment of these mice resulted in DREAM
loss and a gain of MYB-MuvB assembly.
For simplicity, we will refer to the mutant allele of p107 as
p107D, the conditional allele of p130 as p130fl, and its Cre-inactivated form as p130 –. At 8 weeks of age, UBC-CreERT2 p107D/D
2

p130fl/fl mice were injected with tamoxifen (Supplemental Figure 1A; supplemental material available online with this article;
https://doi.org/10.1172/JCI140903DS1). We confirmed successful deletion of p130 exon 2 in the brain, heart, liver, kidney,
spleen, bone, and tail by PCR at 1 week after injection, and also
demonstrated that it persisted 2 years after tamoxifen treatment in
p107D/D p130 –/– mice (Supplemental Figure 1, B–D). We next determined the protein levels of both p107 and p130 in p107D/D p130fl/fl
control and p107D/D p130 –/– mice. We prepared cell lysates from the
liver and spleen 4 weeks after tamoxifen administration. Western
blotting demonstrated that the p130 protein was undetectable in
both the liver and spleen of p107D/D p130 –/– mice, further validating
successful deletion of p130 (Figure 1B). Additionally, p107D protein was detectable in the livers and spleens of p107D/D p130fl/fl and
p107D/D p130 –/– mice.
To validate loss of DREAM assembly in p107D/D p130 –/– mice,
we performed ChIP-qPCR assays to interrogate p107 and B-MYB
occupancy at the promoter for Mybl2, the gene for B-MYB itself
and a known DREAM target (23, 28, 30, 39, 40). We designed
primer pairs to encompass the CDE and CHR elements at the
transcriptional start site (TSS), as well as a –1 kb upstream control
(Figure 1C). Since p130 is absent in p107D/D p130 –/– mice, we surveyed p107D occupancy and found it present at the Mybl2 promoter in p107D/D p130fl/fl mice, indicative of some p107-E2F4 binding
at the CHR site independent of DREAM (Figure 1C). Occupancy
of p107D at this site was diminished in p107D/D p130 –/– mice and this
was coupled with a marked increase in B-MYB occupancy, consistent with MYB-MuvB binding and displacing p107D-E2F complexes when p130 was no longer able to assemble into DREAM (Figure
1C). We also confirmed DREAM disruption in p107D/D p130 –/– mice
using an in vitro promoter pulldown assay that relies on tandem
CDE and CHR elements for stable DREAM binding (Supplemental Figure 2A). In these experiments, p130 was detectable on this
probe in p107D/D p130fl/fl–derived extracts, but not p107D/D p130 –/–
(Supplemental Figure 2B). Furthermore, p107D was undetectable
on this probe in either genotype of extract, consistent with its
inability to be assembled into DREAM (refs. 36, 37 and Supplemental Figure 2B). Collectively, these data demonstrated that
p130 protein expression was missing in p107D/D p130 –/– mice, leading to compromised DREAM assembly and its replacement with
MYB-MuvB. This suggests that phenotypes from p107D/D p130 –/–
mice will reveal the role of DREAM in adult mammals.
p107D/D p130 –/– mice exhibit compromised renal function and
disrupted tissue structure in multiple organs. Cohorts of 8-week-old
UBC-CreERT2 p107D/D p130fl/fl mice were injected with a course
of tamoxifen (p107D/D p130 –/–) and aged alongside tamoxifeninjected p107D/D p130fl/fl control mice. There was a 16% reduction
in lifespan for p107D/D p130 –/– compared with controls that was significantly different (log-rank test, P = 0.0236, Figure 2A). Lifespan
was similar for both male and female mice and their demise was
often without prior symptoms. Some p107D/D p130 –/– mice displayed
distress characterized by shallow breathing and a disheveled coat
at this age, and these “endpoint” mice were euthanized for further
investigation. In contrast, p107D/D p130fl/fl controls experienced
classical aging characterized by kyphosis and predictable endpoints. To explore the underlying causes of premature mortality
in p107D/D p130 –/– mice, we examined tissues from p107D/D p130 –/–
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Figure 1. DREAM assembly is disrupted in p107D/D p130–/– mice. (A) Either
one of the RB-like proteins, p107 or p130, can participate in DREAM
assembly by binding to MuvB in WT mice and repressing transcription. In
p107D/D p130+/+ mice, the p107D mutation prevents it from binding MuvB,
rendering p107D unable to participate in DREAM assembly but still able to
form p107-E2F complexes at CHR elements. p130 is now the only RB-like
family member able to mediate DREAM assembly in p107D/D p130+/+ mice.
In p107D/D p130–/– mice, ablation of p130 (p130–/–) combined with p107D
prevents DREAM assembly. The MuvB core now binds to B-MYB to form
MYB-MuvB and activates transcription. (B) Protein extracts were prepared
from the livers and spleens of 3-month-old p107D/D p130–/– and p107D/D
p130fl/fl control mice. The expression of p107D and p130 protein levels was
detected by Western blotting, and tubulin served as a loading control. (C)
ChIP-qPCR assay to detect p107D and B-MYB binding at the TSS of Mybl2,
a known DREAM target. Illustration depicts the primers used for qPCR
and the regions of interest: black arrows indicate the negative control 1
kb upstream of the TSS, and red arrows indicate an approximately 100 bp
region surrounding the TSS and containing CDE (blue box) and CHR (green)
motifs. Chromatin was prepared from livers, and p107 and B-MYB antibodies were used to precipitate associated DNA (n = 4 for each). Graphs show
mean quantities of the indicated genome locations precipitated, and error
bars indicate 1 SD. Two-way ANOVA was performed for each graph, and
significance levels are indicated (**P < 0.01; ****P < 0.0001).

mice at their endpoint and compared them histologically with
control mice at the end of their full lifespan. There was little evidence to support ectopic cell proliferation in these mice. Although
some p107D/D p130 –/– mice displayed enlarged organs, there were
no significant differences in average mass of livers, spleens, or kidneys (Supplemental Figure 3). Examination of H&E-stained tissues failed to reveal hyperplasia, and Ki67 staining levels and patterns were not altered between genotypes (Supplemental Figure
4). However, H&E staining revealed abnormalities in the heart,
kidney, liver, and spleen of p107D/D p130 –/– mice (Figure 2B). Distinctive extracellular, amorphous, hypocellular, and eosinophilic
material in these tissues suggested the presence of amyloid fibril
deposits. These were found markedly and diffusely in the interstitium of the heart and kidneys, expanding vessel walls in the liver,
and on the periphery of the white pulp extending to the red pulp of
the spleen (Figure 2B, indicated by arrows).

The kidneys of p107D/D p130 –/– mice displayed the most visually dramatic deposits with diffusely expanded interstitium, from
the cortex to the medulla with variable glomerular involvement
(Figure 2B). Importantly, the renal tubular epithelium was swollen
due to cytoplasmic vacuolation, consistent with deposition leading to progressive decline in renal function (41–43). Indeed, almost
90% of endpoint p107D/D p130 –/– mice possessed this type of organ
damage, whereas the other affected organs were observed much
less frequently (Figure 2C). To investigate kidney function, we
collected urine from endpoint p107D/D p130fl/fl and p107D/D p130 –/–
mice and resolved equal volumes of urine by SDS-PAGE to search
for evidence of proteinuria (44). All samples showed evidence
of murine major urinary proteins (MUPs); however, the urine of
p107D/D p130 –/– mice included a prominent approximately 60 kD
band that we confirmed by mass spectrometry to be serum albumin (Figure 2D), indicating albuminuria in these mice (45). Last,
we tested the serum creatinine level in endpoint mice and determined that it was significantly elevated in p107D/D p130 –/– mice
(Figure 2E). These data suggest that at their endpoint, p107D/D
p130 –/– mice exhibited defective kidney function. This is consistent
with histological findings in the kidney, and together they indicate
kidney failure is the most common ailment in p107D/D p130 –/– mice.
Because sudden mortality in a portion of p107D/D p130 –/– mice prevented physiological and histological investigation, it is possible
some p107D/D p130 –/– mice succumbed to a more rapid cause of
death such as cardiac arrest. Overall, multiple organs were damaged in p107D/D p130 –/– mice, leading to premature mortality.
Systemic amyloidosis is evident in p107D/D p130 –/– mice. We
investigated the affected organs for potential amyloid deposition
through histological stains and transmission electron microscopy
(TEM). Heart, kidney, liver, and spleen tissue sections from p107D/D
p130 –/– mice were stained with Congo red and examined under
bright field optics and polarized light (46–48). This demonstrated that weakly stained eosinophilic material corresponded with
regions of apple-green birefringence, a hallmark of amyloid fibril
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Figure 2. p107D/D p130–/– mice have shortened lifespan and compromised organ function. (A) Cohorts of p107D/D p130–/– (n = 30) and p107D/D p130fl/fl control
mice (n = 37) were aged to humane endpoints. Kaplan-Meier survival plots reveal survival proportions and a log-rank test was used to compare outcomes
(P = 0.0236). (B) H&E staining of tissues obtained from p107D/D p130fl/fl and p107D/D p130–/– mice at endpoint. Examples of poorly staining homogeneous,
acellular, eosinophilic areas found in p107D/D p130–/– mice are indicated by arrows. Data are representative of 21 p107D/D p130fl/fl and 25 p107D/D p130–/– mice.
Scale bars: 400 μm for heart, liver, and spleen. Scale bars: 100 μm for kidney. (C) Frequency of histologic abnormalities in p107D/D p130fl/fl (n = 21) and p107D/D
p130–/– mice (n = 25) for each of the indicated organs. (D) Urine samples were collected from endpoint p107D/D p130fl/fl and p107D/D p130–/– mice, and proteins
were resolved on SDS-PAGE gel and stained with Coomassie blue. MUPs, major urinary proteins. (E) Serum samples were collected from endpoint mice and
were analyzed for levels of creatinine. Bar graph represents mean quantities for the indicated genotypes, and error bars indicate 1 SD (n = 8).
****P < 0.0001, by Student’s t test.

deposition (Figure 3, A–D). The presence of amyloid fibril structures in the medullar regions of kidney tissue was confirmed by
TEM from FFPE tissue sections (Figure 3E). Measurement of these
medullar amyloid fibrils revealed a mean diameter of 12 nm that
was consistent with amyloidosis (ref. 49 and Figure 3F). We similarly detected fibrils using TEM in heart and liver tissues of p107D/D
p130 –/– mice (Figure 3, G–H). These experiments confirmed that
the disrupted tissue structures observed in the heart, kidney, liver,
and spleen of p107D/D p130 –/– mice were amyloid in nature.
We next determined the prevalence and impact of amyloids
in p107D/D p130 –/– mice compared with p107D/D p130fl/fl controls.
Heart, kidney, liver, spleen, and brain tissue sections from p107D/D
p130 –/– and control mice were stained with Congo red and scored
to quantitate amyloid deposition based on the quantity of affected area on a scale from 0 to 3 (Supplemental Figure 5). Amyloid
deposition scores were plotted for p107D/D p130 –/– and control mice
for each age cohort (1-year-old and endpoint mice) (Figure 4A).
We also enumerated these amyloid deposition scores with other
abnormal histological features, including relative degree of cel4

lular degeneration and inflammatory cell infiltrates, and plotted
the aggregate score for each mouse on an ordinal scale from 0 to
3 that is representative of the observed diagnostic severity (Supplemental Figure 5 and refs. 50, 51). In heart, kidney, liver, and
spleen, p107D/D p130 –/– mice consistently had increased amyloid
deposition, cellular degeneration, and inflammation at their endpoint compared with p107D/D p130fl/fl control mice (Figure 4B), and
a similar trend was also apparent in comparisons of 1-year-old
p107D/D p130 –/– mice and their age-matched controls. Notably, the
striking amyloid deposition and other histologic abnormalities
found in these tissues were absent from the brain (Figure 4, A and
B and Supplemental Figure 6). Collectively, these results indicate
p107D/D p130 –/– mice accumulated extensive amyloid fibril deposition in the heart, liver, kidney, and spleen, leading to defects in
normal organ structure and function. These characteristics are
indicative of systemic amyloidosis in p107D/D p130 –/– mice.
Apolipoproteins predominate in amyloid fibrils and are overexpressed in p107D/D p130 –/– mice. There are more than 35 amyloid
subtypes that have been identified in humans (1, 2). To relate the
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Figure 3. Systemic amyloidosis in p107D/D p130–/– mice.
(A–D) Tissue sections of heart (A), kidney (B), liver
(C), and spleen (D) from endpoint p107D/D p130–/– mice
were stained with Congo red. Bright field images
were captured along with corresponding apple green
birefringence under polarized light. Scale bars: 20 μm.
(E) FFPE tissues were processed for TEM. Ultrastructure of acellular material in the kidney is shown. Black
arrows indicate fibril structure in this organ. Scale bars:
2 μm and 1 μm (enlarged inset). (F) Fibril diameters
in kidney TEM images were measured. Bar graph
represents mean diameter obtained from individual
fibril measurements, and error bars indicate 1 SD (n =
9). (G–H) TEM images of FFPE heart (G) and liver (H)
tissue. Black arrows indicate areas of fibril deposition.
For orientation, the asterisk indicates mitochondria in
cardiomyocytes, and the pound sign denotes red blood
cells in a hepatic capillary.

amyloidosis phenotype in p107D/D p130 –/– mice with human clinical subtypes, we utilized fluorescent optics of Congo red–stained
tissue to identify amyloid deposits (Figure 5, A and B). We then
performed laser-capture microdissection from FFPE tissue sections and used tandem mass spectrometry to determine its protein composition (LMD/MS) (refs. 52–54 and Figure 5C). In LMD/
MS analysis, mutations in amyloid-causing genes correlate with
abundance of their encoded proteins in amyloid deposits (52).
Combined with the increased specificity enabled by focusing only
on the Congo red–stained areas, highly abundant proteins in our
analysis might be amyloidogenic in p107D/D p130 –/– mice. Within
this proteome, “amyloid signature proteins” were present, which
serve as an internal control to denote that amyloid deposition is
present. These include apoE, APCS, and possibly clusterin and
vitronectin (52, 55, 56). Therefore, by examining this enriched
Congo red–stained proteome for the most abundant proteins pres-

ent, we can identify causative protein candidates from the amyloid
plaques in p107D/D p130 –/– mice.
LMD/MS analysis was performed on hearts, kidneys, livers,
and spleens from endpoint p107D/D p130 –/– mice. This identified
a number of known amyloidogenic proteins, as well as common
amyloid-accompanying peptides. A representative list of proteins that are known to be causative or associated with amyloidosis in humans and present in an endpoint p107D/D p130 –/– liver is
shown (Table 1). Consistent with human clinical cases, the most
abundant protein identified in all samples was apoE. Therefore,
we normalized spectral counts from each sample to its own apoE
and compared the abundance of the remaining amyloidogenic
and amyloid-accompanying proteins. Figure 5D shows a heatmap
depicting relative spectral counts for each protein across 5 identically microdissected samples. Among the known amyloidogenic
proteins, apoA-IV consistently had the highest normalized spec-
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Figure 4. Tissue distribution and disease severity of
amyloidosis in p107D/D p130–/– mice. (A) Tissues from
1-year-old and endpoint mice from p107D/D p130fl/fl and
p107D/D p130–/– cohorts were scored for amyloid deposition on a scale of 0–3 (n = 6). Average scores were
plotted for 1-year-old and endpoint mice and error bars
represent 1 SD. Means were compared by 2-way ANOVA
and significance levels are indicated (***P < 0.001;
****P < 0.0001; and NS is not significant, P > 0.05).
(B) Tissues from 1-year-old and endpoint mice from
p107D/D p130fl/fl and p107D/D p130–/– cohorts were scored
for 3 criteria (amyloid deposition, cellular degeneration,
inflammation) on a scale of 0–3 (n = 6). Scores were
aggregated for each mouse and plotted. Mean scores
are indicated along with 1 SD. Means were compared by
2-way ANOVA, and significance levels are indicated
(*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001;
and NS, P > 0.05).

tral counts (Figure 5D), followed by apoA-II and apoA-I (Figure
5D). Immunoglobulin light and heavy chains were also detected in
most of these samples at relatively low spectral counts (Figure 5D).
These data suggest that apolipoproteins were the most likely cause
of amyloidosis in p107D/D p130 –/– mice.
Amyloid tissue deposition patterns identified by histological
analyses and amyloidogenic proteins identified by LMD/MS in
p107D/D p130 –/– mice suggest apoA-IV, apoA-II, or apoA-I, or a combination of these, as the cause of amyloidosis in these mice. Since
DREAM is a transcriptional repressor and its loss promotes assembly of the activating MYB-MuvB complex, we investigated expression levels of these apolipoproteins. We performed qPCR analysis of RNA isolated from livers of 3-month-old, 1-year-old, and
endpoint p107D/D p130fl/fl and p107D/D p130 –/– mice (Figure 5, E–G).
Each of Apoa1, Apoa2, and Apoa4 were found to be overexpressed
in at least 1 of the time points investigated. Only Apoa4 was significantly increased in p107D/D p130 –/– mice at all ages of investigation (Figure 5G), and its protein levels were approximately 4-fold
increased in liver extracts from 3-month-old p107D/D p130 –/– mice
(Figure 5H), further suggesting that it is the best candidate to be
a causative protein in the amyloidosis observed. In addition, we
investigated the expression of amyloid-associated components
albumin, APCS, and ApoE. Consistent with an associated role,
Alb, Apcs, and Apoe expression in the livers of p107D/D p130 –/– mice
was unaltered (Supplemental Figure 7).
An alternative interpretation of the LMD/MS data is that,
although the spectral counts for immunoglobulin chains were
low, they may play a causative role too. Since DREAM is known
to function in proliferative control, and immunoglobulin amyloidosis is common in myeloma patients, we investigated this possibility further. We found the expression of Ighm to be significantly
increased in the bones and spleens of 1-year and endpoint p107D/D
p130 –/– mice compared with controls (Supplemental Figure 8).
However, a key difference between apolipoprotein- and immu6

noglobulin-based amyloidoses in human patients is the presence
of amyloid deposits in bone marrow and the gastrointestinal tract
(57). H&E- and Congo red–staining in endpoint p107D/D p130 –/–
mice did not identify amyloid deposits in bone marrow, nor did
staining reveal the presence of abnormally proliferating plasma
cells (Supplemental Figure 9A). Examination of the small intestines of endpoint p107D/D p130 –/– mice stained with Congo red
showed scattered amyloid deposits, but nothing distinct by H&E
staining as in the previously described organs above (Supplemental Figure 9B). Overall, the lack of bone marrow amyloids and only
minor intestinal amyloids, but prominent cardiac, renal, hepatic,
and splenic involvement, was most consistent with an apolipoprotein-derived amyloid condition. In addition, apolipoprotein
misexpression and greater detection levels in LMD/MS experiments suggest that they are the more likely cause of amyloidosis in
p107D/D p130 –/– mice. Last, the most consistent and highly overexpressed apolipoprotein in the liver was apoA-IV, and its prominent
detection in amyloids indicates that it was the most likely source of
misexpressed protein to seed amyloid formation.
DREAM disruption leads to H2AZ loss at apolipoprotein genes.
Based on MYB-MuvB binding to the Mybl2 promoter upon p130
deletion in our initial characterization of this genetic model, we
sought to determine whether DREAM loss misregulated apolipoprotein genes. A genome-wide analysis of predicted CHR and CDE
motifs has identified candidates for DREAM/ MYB-MuvB regulation (20). From this data set, Apoa1 and Apoa4 were found to possess both elements, and others, such as Alb and Apoa2, were found
to possess CHR motifs. We performed quantitative ChIP-qPCR
assays on chromatin from livers of 3-month-old mice to determine
whether DREAM/MYB-MuvB bind any of these promoters (Figure 6, A–D). We detected p107D binding to the TSS region of each
of these genes in p107D/D p130fl/fl mice. However, the recruitment
of p107D was significantly reduced in p107D/D p130 –/– livers at Apoa1
and Apoa4 promoters (Figure 6, A and C). The decrease in p107D
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Figure 5. ApoA-IV is the most abundant
amyloidogenic protein in p107D/D p130–/–
amyloid deposits. (A) H&E staining of kidney
from an endpoint p107D/D p130–/– mouse.
Arrows indicate acellular eosinophilic material.
Scale bar: 50 μm. (B) Congo red staining of a
serial section of the same kidney as in A. Black
arrows indicate the same acellular material
under bright-field optics as in A. White arrows
mark the same locations under polarized
and fluorescent optics. Scale bars: 50 μm. (C)
Schematic illustration of LMD/MS procedure:
Congo red–positive regions were laser captured and processed for mass spectrometry to
identify peptides present in amyloids. (D) Per
spectral match quantities were scaled relative
to the most abundant protein in each sample,
apoE. Rows (proteins) were clustered and values are represented as indicated by the scale
at the bottom. Each column represents an
organ from an endpoint p107D/D p130–/– mouse.
(E–G) Total RNA was used to synthesize cDNA.
Gene expression was determined by qPCR
in 3-month-old, 1-year-old, and endpoint
p107D/D p130fl/fl and p107D/D p130–/– mice and
normalized to Gapdh for each age group (n =
4). Bar graphs show mean expression values
for Apoa1 (E), Apoa2 (F), Apoa4 (G) and error
bars represent 1 standard deviation. Values
are normalized to that of p107D/D p130fl/fl at
each age for each gene. Two-way ANOVA was
performed for each gene and significance
levels are indicated (****P < 0.0001; NS, P >
0.05). (H) Protein extracts from the livers of
3-month-old p107D/D p130fl/fl and p107D/D p130–/–
mice were Western blotted for the indicated
proteins. Numerical values represent band
intensity ratio of apoA-IV relative to vinculin.

occupancy was accompanied by an increase in B-MYB at the same
locations, comparable to what was observed at the Mybl2 promoter (Figure 1C) that is indicative of MYB-MuvB binding (Figure
6, A and C). H2AZ — the histone H2A variant that accompanies
DREAM-mediated repression in lower organisms (17) — was similarly analyzed. We performed ChIP-qPCR for H2AZ at Apoa1 and
Apoa4 gene bodies and saw a marked decrease in p107D/D p130 –/–
livers (Figure 6, A and C). Importantly, Apoa2 and Alb exhibited
only background levels of H2AZ that were not altered between

genotypes, suggesting that these genes are not bona fide DREAM
targets (Figure 6, B and D). Overall, these data provide evidence of
direct transcriptional regulation of Apoa1 and Apoa4 by DREAM/
MYB-MuvB through the CHR and CDE motifs found in their proximal promoters. Furthermore, Apoa1 and Apoa4 lost H2AZ from
their gene bodies when DREAM loss was replaced by MYB-MuvB.
These data connect DREAM assembly defects to loss of transcriptional control of apolipoprotein genes, which led to protein overexpression and systemic amyloidosis in p107D/D p130 –/– mice.
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Table 1. LMD/MS analysis of an endpoint p107D/D p130–/– liver
Identified peptides
Apolipoprotein EB
Serum albuminB
Apolipoprotein A-IVA
Apolipoprotein A-IIA
VitronectinB
ClusterinB
Serum amyloid P-componentB
Apolipoprotein A-IA
Ig κ chain
Ig μ

Per spectral match
34
33
21
9
9
7
6
3
3
3

Per spectral match quantities for each protein in the amyloid samples are
shown in descending order. APresumptive amyloidogenic proteins. BKnown
amyloid-associated proteins.

Discussion

In the present study, we demonstrated that loss of DREAM
assembly led to the development of systemic amyloidosis in adult
p107D/D p130 –/– mice. The absence of DREAM increased MYBMuvB recruitment to Apoa1 and Apoa4 promoters and was correlated with reduced H2AZ levels and overexpression of Apoa1
and Apoa4 genes (Figure 7A). These mice developed extensive
amyloid deposition in the heart, kidney, liver, and spleen but not in
the brain or bone. Using mass spectrometry, we discovered similar
amyloidogenic and amyloid signature proteins in affected organs
that implicated apoA-IV as the most likely causative amyloidogenic protein in p107D/D p130 –/– mice (Figure 7B). This condition led to
compromised renal function, and likely other organ defects, and a
shorter lifespan for p107D/D p130 –/– mice (Figure 7C). Overall, this
mouse model represents an important milestone in understanding idiopathic amyloidosis cases.
The phenotype of p107D/D p130 –/– mice characterized by AApoAIV amyloidosis includes other provocative similarities with clinical
reports of this condition. Amyloid deposition in p107D/D p130 –/–
mice was most apparent in kidneys and found throughout the renal
interstitium between the cortex and medulla. Similarly, the first
reported case for AApoAIV and subsequent analysis of additional
patients with AApoAIV revealed extensive amyloid deposition in
the interstitial space of the medulla (16, 58). LMD/MS analysis of
these patients identified apoA-IV as the major constituent of amyloid fibrils in the kidney along with apoE, APCS, and serum albumin (16, 58), thus matching our findings here. ApoA-I and immunoglobulin light chain peptides were also present in AApoAIV, but
at lower levels (16, 58). The involvement of apoE, APCS, and serum
albumin in forms of amyloidosis outside of the affected organs
observed here further suggests apoA-IV is most likely the causative
component of the amyloid. Therefore, our analysis of systemic
amyloidosis in p107D/D p130 –/– adult mice is consistent with clinically observed characteristics of AApoAIV. AApoAIV is a newly
described form of amyloidosis that has only begun to be appreciated when revealed by LMD/MS analysis. The lack of an underlying mutation in the apoA-IV–encoding gene in these patients has
created challenges in identifying the source of this disease and its
8

classification. Our data from p107D/D p130 –/– mice indicate that apolipoprotein misexpression and amyloid deposition may result from
a host of different sources that converge on H2AZ regulation and
underscore our finding of this epigenetic source of amyloidosis.
Unlike hereditary amyloidosis caused by apoA-I or apoA-II
whereby genetic mutations in Apoa1 or Apoa2 lead to α-helix to
β-sheet conformational changes in protein structure that ultimately manifest as amyloid fibrils (5), no such genetic variants
have been implicated in AApoAIV (15). Binding with HDL or
protein-protein interactions are thought to protect apoA-IV’s
amyloidogenic hotspot regions within its core α-helices (5). It can
therefore be surmised that overexpression of Apoa4 may create
an imbalance in the concentration of apoA-IV compared with
its partner lipids or proteins, thereby increasing the propensity
to form amyloid fibrils. Herein, we showed that loss of DREAM
assembly in p107D/D p130 –/– mice led to consistent overexpression
of Apoa4 at every age we investigated, whereas Apoa1 overexpression only occurred in 3-month-old mice. We observed a direct
interaction of p107 and B-MYB with the Apoa1 and Apoa4 TSSs,
which contain putative CHR and CDE sites (20). It is known that
loss of DREAM causes a dynamic shift in which the transcriptional activator MYB-MuvB occupies the start site and activates
expression (23, 36). Our data demonstrated this switch occurred
with a concomitant reduction of the H2AZ repressive mark within
Apoa1 and Apoa4 gene bodies. This suggests that these are specific and important DREAM target genes and that a combination
of H2AZ reduction and MYB-MuvB activation increases their
expression. Prior work on worms and flies established DREAM as
a regulator of gonadal and sex-specific gene expression in addition to cell-cycle control (59); our study indicates that apolipoprotein gene expression is a critical category of DREAM target genes
required in mammalian physiology.
In this study, we have shown that DREAM loss and gain of
MYB-MuvB activated expression of Apoa4 to drive AApoAIV-mediated amyloidosis. This suggests that enhancement of DREAM
or attenuation of B-MYB may offer therapeutic benefit in treating
AApoAIV. Additionally, understanding other epigenetic regulators
that may help to control H2AZ deposition levels at these genes
are also potential targets to ameliorate expression of amyloidosis-causing apolipoprotein genes in the future.

Methods

Mouse genetics. We utilized our mice that were homozygous for
Rbl1tm1.1Fad (referred to as p107D/D, ref. 36) and Rbl2tm2.1Tyj (referred to
as p130fl/fl, The Jackson Laboratory, stock 008177, ref. 35), in which
exon 2 of p130 was flanked by loxP sites. Experimental mice possessed the Ndor1Tg(UBC-cre/ERT2)1Ejb transgene (38) that was also obtained
from The Jackson Laboratory (stock 007001); control animals were
p107D/D p130fl/fl. All mice received i.p. administration of tamoxifen at
8 weeks of age (75 mg/kg body weight administered in corn oil every
24 hours for 3 consecutive days). This experimental design with a
Cre-deficient cohort allowed us to control for potential tamoxifeninduced liver injury in this study (60, 61).
Genotyping p130 exon 2 deletion in mice. DNA was isolated from
the tail, muscle, liver, heart, brain, testis, and bone from mice 1 week
and approximately 2 years after tamoxifen administration. PCR was
performed to amplify the region surrounding exon 2, and the prod-
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Figure 6. B-MYB is recruited to Apoa1 and Apoa4 promoters in DREAM assembly–deficient p107D/D p130–/– mice. (A–D) Chromatin was prepared from
livers of 3-month-old p107D/D p130fl/fl and p107D/D p130–/– mice and utilized in ChIP assays to detect p107D, B-MYB, and H2AZ occupancy at promoters (n =
4). For each of Apoa1 (A), Apoa2 (B), Apoa4 (C), and Alb (D) genes, a schematic is shown to illustrate primer annealing sites. Arrows depicting primers are
color coded: black represents a neutral location 1 kb upstream of the TSS; red is an approximately 100 bp region encompassing the CHR and/or CDE motifs
near the TSS; purple is within the gene body. ChIP protein targets p107, B-MYB, and H2AZ are organized in columns across the top. Bar graphs depict the
mean quantity of chromatin associated with each protein target as detected by qPCR and error bars represent 1 standard deviation. Two-way ANOVA was
performed for each graph and significance levels are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; and NS, P > 0.05).

ucts were resolved on agarose gels using standard protocols. Primer
sequences are listed in Supplemental Table 1.
Western blotting. Tissues were collected from mice and homogenized using an automatic homogenizer in complete RIPA buffer with
protease inhibitors (MilliporeSigma, S8820) and incubated for 1 hour
on ice. Samples were centrifuged at 12,000g in a 4°C centrifuge. The
supernatant was collected, and protein concentration was determined
by Bradford assay. Lysates were mixed with 6× SDS loading dye buffer
and resolved using standard SDS-PAGE protocols in 8% acrylamide
gels. Antibodies used for blotting were p107 (MyBioSource, anti–p107
rabbit antibody MBS440044), p130 (Santa Cruz Biotechnology, anti–
p130 rabbit antibody SC-317), apoA-IV (Cell Signaling Technology,
anti–ApoA4 mouse antibody 5700), tubulin (Cell Signaling Technology, anti–tubulin rabbit antibody 2125), and vinculin (Cell Signaling
Technology, anti-vinculin rabbit antibody 4650). Band intensities
were measured and analyzed in ImageJ, version 1.53c (NIH).

ChIP. ChIP assay was performed as described previously (62, 63).
Livers were harvested from 3-month-old p107D/D p130fl/fl and p107D/D
p130 –/– mice midmorning. Livers were weighed and cut into 60 mg
pieces that were then homogenized in ice-cold PBS using an automatic homogenizer. Samples were incubated with 1% formaldehyde
for 10 minutes on a rotator at room temperature. Samples were then
sonicated. Next, 50 μL protein A/G Dynabeads (Invitrogen, Thermo
Fisher Scientific) were premixed with ChIP antibodies (p107: 10 μg,
MyBioSource, anti-p107 rabbit antibody MBS440044; B-MYB: 10 μg,
MilliporeSigma, anti–B-MYB mouse antibody MABE886; H2AZ: 5 μg,
Abcam, anti–histone H2A.Z rabbit antibody ab4174), and then combined with lysed and sonicated samples and incubated overnight at 4°C
with rotation. Dynabeads were then washed and chromatin was eluted using elution buffer (1% SDS, 0.1 M NaHCO3), and after de-crosslinking DNA was isolated. The resulting ChIP DNA was analyzed by
qPCR (as described above) with primer pairs designed to amplify –1 kb
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Figure 7. Loss of DREAM assembly in p107D/D p130–/– mice promotes
MYB-MuvB assembly that drives systemic AApoAIV amyloidosis due to
constitutive overexpression of Apoa4. A schematic model illustrating the
development of systemic AApoAIV amyloidosis in p107D/D p130–/– mice. At
3 months of age, ablation of p130 by Cre activation combined with mutant
p107D prevents DREAM assembly and promotes MYB-MuvB activation of
transcription. In the liver, MYB-MuvB occupies CHR and CDE motifs at the
TSSs of apolipoprotein genes, particularly Apoa4, leading to reduced H2AZ
occupancy within its gene body and constitutive overexpression (A). In
1-year-old p107D/D p130–/– mice, small amyloid deposits are evident in the
heart, liver, kidney, and spleen (B). By 2 years of age, apoA-IV deposition was
more pronounced in the heart, liver, and spleen. Deposition in the kidney of
most p107D/D p130–/– mice led to organ failure and reduced survival (C).

upstream of the TSS (neutral location), primers to amplify the proximal promoter regions, and primers to amplify within the gene bodies of
Apoa1, Apoa2, Apoa4, Alb, and Mybl2 (Supplemental Table 1).
Ccna2 promoter pulldown. Primer pairs (Supplemental Table 1)
were used to amplify the promoter region of Ccna2 containing a CDE
and a CHR and Actb, such that only 1 primer was biotinylated, resulting
in the amplicon being biotinylated at 1 end. These were purified using
a PCR cleanup kit (Invitrogen, Thermo Fisher Scientific). Dynabeads
were washed and prepared in 2× binding and washing buffer (10 mM
Tris-HCl pH 7.5, 1 mM EDTA, 2 M NaCl). An equal volume of purified
PCR fragments in nuclease-free water was added and incubated for
15 minutes at room temperature on a rotator. Dynabeads were then
washed 3× with 1× binding and washing buffer and after the final
wash, all buffers were removed from the tube. Lysates were obtained
from livers of 3-month-old p107D/D p130fl/fl and p107D/D p130 –/– mice as
described above. Next, 1 mg of protein in RIPA lysis buffer was added
to the Dynabeads as well as 0.1 μL of 10% NP-40 and mixed overnight
at 4°C. Dynabeads were then washed twice in lysis buffer and 50 μL
release buffer (10 mM EDTA pH 8.2 with 95% formamide) was added
and incubated for 2 minutes at 90°C. Supernatant containing bound
proteins was collected, 5× SDS loading dye was added, and proteins
were resolved by SDS-PAGE and identified by Western blotting.
Tissue preparation and staining. Mice were either aged until their
endpoints or euthanized at an earlier time point. The following organs
were collected and fixed in formalin: brain, heart, lungs, liver, kidney, spleen, ovaries, testes, and lymph nodes. Tissues were processed
and sectioned in the Molecular Pathology Core Facility at Robarts
Research Institute. Staining with H&E or Congo red was carried out
by the core facility using standard methods.
10

Scoring amyloid damage to tissues. Tissues stained with H&E or
Congo red were scored for amyloid deposition, cellular degeneration,
and inflammation each on a scale of 0–3 as per the criteria shown in
Supplemental Figure 6. Cumulative scores from all 3 categories were
used to determine an aggregated, semiquantitative pathology score
for each tissue and timepoint.
Proteinuria assay. Urine from mice was collected and assayed for
protein as previously described (44). Briefly, urine was directly collected
into 1.5 mL tubes. Nine parts urine was mixed with 1 part 10× SDS loading dye buffer. Next, 10 μL urine per mouse was resolved by SDS-PAGE
gels and proteins were stained with Coomassie blue to visualize proteins.
Creatinine assay. Whole blood was collected through cardiac
puncture from approximately 2-year-old endpoint mice. Blood was
allowed to clot undisturbed at room temperature for 15 minutes, and
the clot was removed by centrifugation at 2000g for 15 minutes to
separate serum. Serum was diluted 1:1000 and assayed in triplicates
using Abcam creatinine assay kit (ab65340). Samples were measured
fluorometrically using a Wallac 1420 Victor2 microplate reader (PerkinElmer Informatics) at Ex/Em 538/587 nm.
Protein identification. MALDI-MS was performed at the London
Regional Proteomics Centre. Briefly, Coomassie blue–stained bands
were excised and gel-digested using a MassPREP automated digester (PerkinElmer). Peptides were ionized with an AB Sciex 5800 TOF/
TOF using a TOF/TOF Series Explorer data acquisition system. Protein identification was made using the Mascot search engine.
TEM. TEM was performed at the Biotron of Western University
on paraffin-embedded tissue blocks. Fragments of paraffin-embedded tissue were cut into 1 mm3 pieces using a biopsy punch. Using the
methods of Lighezan et al. (64), tissues were deparaffinized in xylene 3
times for 30 minutes at room temperature. Specimens were then rehydrated in a descending series of ethanol solutions followed by rinsing
in 0.1 M cacodylate buffer for 10 minutes. Tissues were then postfixed
in a 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) overnight
(~12 hours) at 4°C and then rinsed in 0.1 M cacodylate buffer. Postfixation was carried out for 1 hour with 1.0% osmium tetroxide in 0.1 M
cacodylate buffer. Specimens were dehydrated in an ascending series
of ethanol solutions and embedded in Spurr’s resin at 60°C for 2 days.
Ultrathin (70 nm) sections were cut using an ultramicrotome (Ultramicrotome Reichert-Jung Ultracut E; Leica Microsystems). Imaging
was carried out using a Philips CM10 transmission electron microscope (Philips Electron Optics), and amyloid fiber diameters were
measured using CM10 image analysis software.
Amyloid subtyping by LMD/MS. Sample preparation and proteomics analysis were performed at University Health Network’s Laboratory
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Medicine Program (Toronto, Canada). A modified method previously
published by Dogan et al. (65), was used for protein extraction from
mouse tissue. Briefly, a 10 μm thick section of FFPE tissue was mounted on a Director slide (NantOmics) and stained with Congo red. Amyloid-positive regions were then extracted with the LMD7000 system
(Leica Microsystems) and collected via gravity in caps of 0.5 mL microtubes containing 35 μL of protein extraction buffer (mix of 10 mM Tris,
1 mM EDTA, and 0.002% Zwittergent 3-16 [Calbiochem]). After tissue
collection, microtubes were centrifuged for 2 minutes at 9295g (Eppendorf microcentrifuge, 5417C). To extract proteins from FFPE matrix, we
heated the samples at 98°C for 90 minutes with occasional vortexing.
Samples were then sonicated in a water bath for 1 hour (VWR Scientific
Aquasonic, P250D), and then digested with 0.5 μg trypsin (Promega)
overnight at 37°C. Digested samples were reduced with 2 μL of 0.1 M
dithiothreitol at 95°C for 5 minutes and diluted with 7 μL of 0.5% trifluoroacetic acid and 0.15% formic acid solution made in LC-MS grade
water. Next, 18 μL of sample was analyzed using nanoflow liquid chromatography-tandem mass spectrometry (nLC-MS/MS).
All samples were analyzed using a hybrid LTQ Orbitrap XL mass
spectrometer coupled to an Easy nLC 1000 liquid chromatography
system (Thermo Fisher Scientific). Peptides were applied to a trap C8
column (150 μm ID × 20 mm, New Objective; 5 μm Magic C8 packing,
Michrom Bioresources) and separated on a reverse phase C18 column
(75 μm ID × 150 mm, New Objective; 3 μm Agilent Pursuit C18 packing, Agilent Technologies) using a linear gradient from 1% to 65% acetonitrile containing 0.1% formic acid over 112 minutes at a flow rate
of 300 nL/min. Eluting peptides were ionized using Nanospray Flex
Ion source (Thermo Fisher Scientific), and the corresponding spectra
in the positive ion mode were obtained under data-dependent acquisition mode. Full MS scans were collected in the orbitrap (400–1500
m/z range, 60,000 resolution), while the top 7 most intense precursor
ions that underwent collisionally induced dissociation at 35 V were
detected by the linear ion trap.
The resulting raw data files were processed using the Proteome Discoverer 1.4 (Thermo Fisher Scientific) and the Sequest HT algorithm. The
fragmentation spectra were searched against the UniProt Mus musculus
database (last modified January 15, 2020). The search parameters were as
follows: the precursor mass tolerance was 7 ppm and the fragment mass
tolerance was set to ±0.05 Da. The peptide FDR was less than 1%. Peptides associated with a high confidence level identification (probability of
identification >90%) were filtered and selected for protein identification.
RT-qPCR. Tissues were collected from mice at different time
points (3-month-old, 1-year-old, and endpoint mice) and processed
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